Ensuring patients’ access to optimal treatment and comprehensive care is the cornerstone of the EHC’s mission.

Certification of Treatment Centres

The EHC is a key partner in the certification of European treatment centres as either ‘European Haemophilia Comprehensive Care Centres’ (EHCCC) or ‘European Haemophilia Treatment Centres’ (EHTC). This certification work began in 2012 through the European Haemophilia Network (EUHANET) project, co-funded by the European Commission, as a way to respond to the large disparities in terms of facilities and services provided by more than 400 treatment centres in Europe.

While the EUHANET project ends in 2015, the voluntary certification of European centres will continue under the joint leadership of the EHC and the European Association for Haemophilia and Allied Disorders (EAHAD).

For more information on the certification of haemophilia treatment centres or the EUHANET project visit EUHANET.

European principles, guidelines and recommendations

The EHC actively supports the production of and helps to disseminate relevant principles of care, guidelines and other recommendations for the treatment and care of haemophilia and congenital bleeding disorders.

These include the European Principles of Haemophilia Care and the new recommendations for optimal use of clotting factors from the European Directorate for the Quality of Medicines and Healthcare (EDQM), an organisation part of the Council of Europe.

A comprehensive list of publications is available in the library section (coming soon).


A component of the EUHANET project is the European Haemophilia Safety Surveillance (EUHASS) system, a pharmacovigilance program to monitor the safety of treatments for people with congenital bleeding disorders in Europe.

The project produces quarterly reports on adverse events in Europe. A detailed annual report with analysis of adverse event rates in function of diagnosis, treatment status and clotting factor concentrates is produced after each full year of surveillance. Reports are distributed to the participating centres, pharmaceutical companies who co-fund the project, national patients’ groups, European and other regulatory authorities (e.g. European Medicines Agency, US Food and Drug Administration) and healthcare professionals providing care for people with haemophilia and other congenital bleeding disorders in Europe. Additionally, EUHASS provides information on clotting factors used in Europe and a rapid-alert system for adverse events.